Aralast NP, or commonly known as Aralast, is an alpha-1 proteinase inhibitor. It's an enzyme replacement that's used as augmentation therapy to manage lung problems (emphysema) in adults with a genetic condition called alpha-1 antitrypsin (AAT) deficiency. This medication helps raise the level of AAT in the body to protect the lungs. Aralast is given as an infusion into the veins (IV) once a week. Side effects include headache and muscle and bone pain.
Augmentation therapy for lung damage (emphysema) due to severe alpha-1 antitrypsin (AAT) deficiency
People with alpha-1 antitrypsin (AAT) deficiency have little to no AAT in their body. AAT, also known as alpha-1 proteinase inhibitor, is an enzyme that your body normally makes to help protect the lungs from damage. Without enough AAT, there's a higher risk for lung problems, like emphysema.
Aralast is an enzyme replacement therapy. It helps restore the levels of AAT in the body to help protect the lungs.
Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. Tell your healthcare professional if you are taking any other prescription or nonprescription (over-the-counter [OTC]) medicine.
People who are immunoglobulin A (IgA) deficient with antibodies against IgA (due to risk of severe allergic reactions)
Augmentation therapy for lung damage (emphysema) due to severe alpha-1 antitrypsin (AAT) deficiency
Augmentation therapy for lung damage (emphysema) due to severe alpha-1 antitrypsin (AAT) deficiency
Augmentation therapy for lung damage (emphysema) due to severe alpha-1 antitrypsin (AAT) deficiency
By signing up, I agree to GoodRx's Terms and Privacy Policy, and to receive marketing messages from GoodRx.
American Lung Association. (2023). Treating and managing alpha-1 antitrypsin deficiency.
Li, Z., et al. (2022). Comparative biochemical efficacy analysis of an alpha1-proteinase inhibitor (Glassia) in patients with alpha-1 antitrypsin deficiency. Pulmonary Pharmacology & Therapeutics.
MediMedia USA, Inc. (2010). Alpha1-proteinase inhibitor (human). Pharmacy & Therapeutics.
MedlinePlus. (2022). Selective deficiency of IgA.
National Heart, Lung, and Blood Institute. (2023). COPD: Alpha-1 antitrypsin deficiency. National Institutes of Health.
National Human Genome Research Institute. (2024). Antibody. National Institutes of Health.
Patel, A., et al. (2023). Biochemistry, immunoglobulin A. StatPearls.
Takeda Pharmaceuticals America, Inc. (2023). ARALAST NP- alpha-1-proteinase inhibitor (human) [package insert]. DailyMed.
Takeda Pharmaceuticals America, Inc. (2024). Aralast NP.
Research prescriptions and over-the-counter medications from A to Z, compare drug prices, and start saving.